A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model

文献类型： 外文期刊

第一作者： Gao, Xintao

作者： Gao, Xintao;Liu, Xingjian;Zhou, Chenghao;Shang, Yuting;Wu, Tong;Zhang, Zhifang;Li, Yinue;Zhu, Xizhou;Jia, Hong;Xin, Ting

作者机构：

关键词： cystic echinococcosis; vaccine; combination adjuvant; ferritin nanoparticle; CpG

期刊名称：INTERNATIONAL JOURNAL OF NANOMEDICINE （ 影响因子：6.5； 五年影响因子：7.7 ）

ISSN： 1178-2013

年卷期： 2025 年 20 卷

页码：

收录情况： SCI

摘要： Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity. Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease. Methods: A ferritin-based Eg95 nanoparticle antigen was prepared and then mixed with a plasmid containing the TLR9 agonist CpG to formulate a novel nanovaccine. The safety and efficacy of the vaccine were evaluated in vitro and in vivo. Results: The nanovaccine induced potent and enduring Eg95-specific humoral and cellular immune responses, as well as protective immunity-associated Th1 polarization supported by the higher ratios of IgG2a/IgG1 and IFN-gamma/IL-4. Meanwhile, this nanovaccines exhibited favorable safety and economic profiles. Conclusion: Our data demonstrated that the ferritin-CpG hybrid is a promising combination adjuvant to upgrade the traditional Quil-A and this combination adjuvant-based nanovaccine presents good potential as an alternative to the commercial one for practical CE control.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序